Back to top
more

Celldex Therapeutics (CLDX)

(Delayed Data from NSDQ)

$23.55 USD

23.55
1,249,780

-2.19 (-8.51%)

Updated Nov 15, 2024 04:00 PM ET

After-Market: $23.53 -0.02 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

What's in the Cards for Celldex (CLDX) this Earnings Season?

With no approved product in Celldex Therapeutics's (CLDX) portfolio, investor focus will remain on immuno-oncology pipeline, which continues to show impressive results.

    Why Is Celldex (CLDX) Down 27% Since the Last Earnings Report?

    Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Celldex's Immuno-Oncology Pipeline Continues to Impress

      On May 25, we issued an updated research report on Hampton, NJ-based Celldex Therapeutics, Inc. (CLDX).

        Celldex (CLDX) Q1 Loss In Line, Revenues Beat, Shares Up

        Celldex Therapeutics, Inc. (CLDX) posted first-quarter 2017 loss of 28 cents per share, which was in line with the Zacks Consensus Estimate

          Celldex Therapeutics (CLDX) Q1 Earnings: What's in Store?

          Celldex Therapeutics, Inc. (CLDX) is expected to report first-quarter 2017 results on May 4. Celldex's performance has been encouraging with a three-quarter average positive surprise of 8.06%.

            What's in Store for GlaxoSmithKline (GSK) in Q1 Earnings?

            GlaxoSmithKline plc (GSK) is scheduled to report first-quarter 2017 results on Apr 26 before market opens. Last quarter, the company delivered a positive earnings surprise of 14.04%.

              Amgen (AMGN) to Report Q1 Earnings: Will it Beat Again?

              We expect biotech major Amgen Inc. (AMGN) to beat expectations when it reports first-quarter 2017 results on Apr 26 after the market closes.

                Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards?

                Eli Lilly and Company (LLY) will report first-quarter 2017 results on Apr 25, before the market opens.

                  What's in Store for Biogen (BIIB) this Earnings Season?

                  Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, will report first-quarter 2017 results on Apr 25, before the market opens.

                    Why Is Celldex (CLDX) Down 4.4% Since the Last Earnings Report?

                    Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                      Celldex (CLDX) Shares Up as Q4 Loss Narrows; Sales Beat

                      Celldex Therapeutics, Inc. (CLDX) posted fourth-quarter 2016 loss of 30 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 34 cents and the year-ago loss of 33 cents.

                        Spectrum (SPPI) Q4 Loss Narrower than Expected, Sales Beat

                        Spectrum Pharmaceuticals, Inc. (SPPI) reported a loss of 22 cents per share in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 26 cents but substantially wider than year-ago loss of 6 cents.

                          Celldex Therapeutics (CLDX) Q4 Earnings: What's in Store?

                          Celldex Therapeutics, Inc. (CLDX) is expected to report fourth-quarter 2016 results on Mar 4 after market close.